ESTIMATED
06/18/2024
06/18/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | $0.00 | $0.00 | $0.00 |
Q2 2024 | 1 | -$0.06 | -$0.06 | -$0.06 |
Q3 2024 | 1 | -$0.01 | -$0.01 | -$0.01 |
LogicBio Therapeutics, Inc. last posted its earnings results on Tuesday, June 18th, 2024. The company reported $-2.43 earnings per share for the quarter, missing analysts' consensus estimates of $-2.1 by $0.33. The company had revenue of 36.00 M for the quarter and had revenue of 287.00 M for the year. LogicBio Therapeutics, Inc. has generated $-13 earnings per share over the last year ($-13.36 diluted earnings per share) and currently has a price-to-earnings ratio of -0.48. LogicBio Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/30/2024 | Q1 2024 | -$2.43 | $36.00 M | $36.00 M | 12/30/2023 | Q4 2023 | -$2.86 | $53.00 M | 09/29/2023 | Q3 2023 | -$3.35 | $3.10 M | $60.00 M | 06/29/2023 | Q2 2023 | -$3.38 | $3.00 M | $78.00 M | 03/30/2023 | Q1 2023 | -$3.83 | $96.00 M | 12/30/2022 | Q4 2022 | -$4.80 | $2.00 M | $0 | 11/14/2022 | Q3 2022 | -$0.21 | -$0.18 | 0.03 | $2.36 M | $2.72 M | 08/15/2022 | Q2 2022 | -$0.24 | -$0.16 | 0.08 | $6.52 M | $3.20 M | 05/16/2022 | Q1 2022 | -$0.28 | -$0.21 | 0.07 | $2.82 M | 03/04/2022 | Q4 2021 | -$0.34 | -$0.29 | 0.05 | $2.03 M | 11/15/2021 | Q3 2021 | -$0.30 | -$0.31 | -0.01 | $2.12 M | 08/09/2021 | Q2 2021 | -$0.24 | -$0.33 | -0.09 | $802,000 | 05/10/2021 | Q1 2021 | -$0.25 | -$0.32 | -0.07 | $461,000 | 03/15/2021 | Q4 2020 | -$0.32 | -$0.29 | 0.03 | $542,000 | 11/09/2020 | Q3 2020 | -$0.41 | -$0.34 | 0.07 | $926,000 | 08/10/2020 | Q2 2020 | -$0.48 | -$0.35 | 0.13 | $965,000 | 05/11/2020 | Q1 2020 | -$0.48 | -$0.41 | 0.07 | $1.02 M | 03/16/2020 | Q4 2019 | -$0.49 | -$0.49 | 0 | $0 | 11/12/2019 | Q3 2019 | -$0.46 | -$0.48 | -0.02 | $0 | 08/13/2019 | Q2 2019 | -$0.41 | -$0.45 | -0.04 | $0 |
---|
A. LogicBio Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates.
A. The conference call for LogicBio Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for LogicBio Therapeutics, Inc.'s latest earnings report can be read online.
A. LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has a recorded annual revenue of $287.00 M.
A. LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has a recorded net income of $287.00 M. LogicBio Therapeutics, Inc. has generated $-13.36 earnings per share over the last four quarters.
A. LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has a price-to-earnings ratio of -0.48 and price/earnings-to-growth ratio is -0.02.